News

Bio-Matrix Scientific has retained a private grant R&D firm to pursue both private and public sector grant funding of research in the area of stem cell therapy for

Cytheris has initiated a phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL). Reportedly, the company’s trial is a further investigation of its investigative

Eli Lilly has reported the sale of Tippecanoe Laboratories (Tippecanoe) manufacturing facility to Evonik Industries (Evonik). Reportedly, the manufacturing site, located in Lafayette, Indiana, will remain in operation

The European Medicines Evaluation Agency (EMEA) has given orphan drug status to ARQ 197, a treatment for Soft Tissue Sarcoma. Medicinal products are designated as orphan drugs by

The company will also demo four new products that are expected to be launched in the next few quarters, which include: In-Vitro Diagnostic Products – BC-5800 five-part hematology

Ziopharm Oncology has reported positive top line interim data from the multicenter randomised phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue

Sosei Group (Sosei) has entered into a deal with Biocopea Limited (Biocopea), a subsidiary of PepTcell, for the drug discovery program, SD281 and its analogues. The company has

Nymox Pharmaceuticals (Nymox) has reported positive and repeatable results for NX-1207 in laboratory studies of human prostate cancer. In addition, local injection of NX-1207 has showed activity in

Generex Biotechnology (Generex) has received FDA price approval for the use of Oral-lyn under the FDA’s Treatment Investigational New Drug (IND) program. The company has previously said that